Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01727336
Title Study of Dalantercept in Patients With Advanced Renal Cell Carcinoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Acceleron Pharma, Inc.
Indications

renal cell carcinoma

Therapies

Axitinib + Dalantercept

Axitinib

Age Groups: adult
Covered Countries USA


No variant requirements are available.